Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives



Page Path
HOME > Search
3 "quality control"
Article category
Publication year
Review Article
Points to consider for COVID-19 vaccine quality control and national lot release in Republic of Korea: focus on a viral vector platform
Jung Hun Ju, Naery Lee, Sun-hee Kim, Seokkee Chang, Misook Yang, Jihyun Shin, Eunjo Lee, Sunhwa Sung, Jung-Hwan Kim, Jin Tae Hong, Ho Jung Oh
Osong Public Health Res Perspect. 2022;13(1):4-14.   Published online February 8, 2022
  • 3,367 View
  • 141 Download
Graphical AbstractGraphical Abstract AbstractAbstract PDF
Due to the global public health crisis caused by the coronavirus disease 2019 (COVID-19) pandemic, the importance of vaccine development has increased. In particular, a rapid supply of vaccines and prompt deployment of vaccination programs are essential to prevent and overcome the spread of COVID-19. As a part of the vaccine regulations, national lot release is regulated by the responsible authorities, and this process involves the assessment of the lot before a vaccine is marketed. A lot can be released for use when both summary protocol (SP) review and quality control testing are complete. Accelerated lot release is required to distribute COVID-19 vaccines in a timely manner. In order to expedite the process by simultaneously undertaking the verification of quality assessment and application for approval, it is necessary to prepare the test methods before marketing authorization. With the prolonged pandemic and controversies regarding the effectiveness of the COVID-19 vaccine against new variants, public interest for the development of a new vaccine are increasing. Domestic developers have raised the need to establish standard guidance on the requirements for developing COVID-19 vaccine. This paper presents considerations for quality control in the manufacturing process, test items, and SP content of viral vector vaccines.
Meeting Report
The 2nd Meeting of National Control Laboratories for Vaccines and Biologicals in the Western Pacific
Hokyung Oh, Jinho Shin, Chung Keel Lee, Masaki Ochiai, Kiyoko Nojima, Chang Kweng Lim, Sanj Raut, Irene Lisovsky, Stella Williams, Ki Young Yoo, Dong-Yeop Shin, Manabu Ato, Qiang Ye, Kiwon Han, Chulhyun Lee, Naery Lee, Ji Young Hong, Kikyung Jung, Pham Van Hung, Jayoung Jeong
Osong Public Health Res Perspect. 2018;9(3):133-139.   Published online June 30, 2018
  • 3,218 View
  • 99 Download
AbstractAbstract PDF

The Second Meeting of the National Control Laboratories for Vaccines and Biologicals in the Western Pacific, was jointly organized by the National Institute of Food and Drug Safety Evaluation of the Ministry of Food and Drug Safety in the Republic of Korea, and by the World Health Organization Regional Office for the Western Pacific.

In the National Lot Release Systems session countries including Canada, China, Japan, Malaysia, Vietnam, and the Republic of Korea, all shared information on their current Lot Release Systems, including current practices and developments in risk-based official lot release of vaccines.

In the session on Quality Control of Blood Products, experts from the National Institute for Biological Standards and Control shared quality control and research results for; blood coagulation factor VIII products, and the measurement of procoagulant activity in immunoglobulin products. Representatives from Japan proposed a regional collaborative study to test aggregated immunoglobulin free from complement activity. A cell-based Japanese encephalitis vaccine potency assay was proposed by representatives from Korea and they also called for voluntary participation of other National Control Laboratories in a collaborative study, on the first Korean Gloydius anti-venom standard. Participants agreed in general to continue communicating, and coordinate presentation of the study results.

National Biobank of Korea: Quality control Programs of Collected-human Biospecimens
Jae-Eun Lee, Ji-Hyun Kim, Eun-Jung Hong, Hye Sook Yoo, Hye-Young Nam, Ok Park
Osong Public Health Res Perspect. 2012;3(3):185-189.   Published online June 30, 2012
  • 1,995 View
  • 15 Download
  • 16 Citations
AbstractAbstract PDF
Personalized medicine is emerging as a main paradigm for risk prediction, pre-diagnosis, and effective prevention and treatment of disease. A large number of human biospecimens and their clinical data are essential resources for the success of personalized medicine as well as other biomedical research. The National Biobank of Korea (NBK) has collected well-annotated and high quality human biospecimens, and distributes them to the Korean biomedical scientists, through the Korea Biobank Project (KBP). The ultimate goal of NBK activities is to promote biomedical research and public health. As of December- 2011, the NBK has collected various human biospecimens from 525,416 participants including 325,952 Korean populations and 199,464 patients. The purpose of this paper is to introduce the KBP and quality control programs for collection of human biospecimens with high quality of NBK.


Citations to this article as recorded by  
  • Multi-omics reveals microbiome, host gene expression, and immune landscape in gastric carcinogenesis
    Chan Hyuk Park, Changjin Hong, A-reum Lee, Jaeyun Sung, Tae Hyun Hwang
    iScience.2022; 25(3): 103956.     CrossRef
  • Biobank for multidrug-resistant tuberculosis research: importance of sequential samples
    Yoohyun Hwang, Jiyeon Kim, Seungkyu Park, Sungweon Ryoo
    Pathogens and Disease.2021;[Epub]     CrossRef
  • Comparison between Cervical Ureaplasma spp. Colonization and the Intensity of Inflammatory Mediators in the Amniotic Fluid Retrieved during Cesarean Delivery in Preterm Birth
    Jingon Bae, Shin Kim, Ilseon Hwang, Jaehyun Park
    International Journal of Environmental Research an.2021; 19(1): 107.     CrossRef
  • Contributions of the UK biobank high impact papers in the era of precision medicine
    Peter Glynn, Philip Greenland
    European Journal of Epidemiology.2020; 35(1): 5.     CrossRef
  • Axes of a revolution: challenges and promises of big data in healthcare
    Smadar Shilo, Hagai Rossman, Eran Segal
    Nature Medicine.2020; 26(1): 29.     CrossRef
  • Is the Random Forest Algorithm Suitable for Predicting Parkinson’s Disease with Mild Cognitive Impairment out of Parkinson’s Disease with Normal Cognition?
    Haewon Byeon
    International Journal of Environmental Research an.2020; 17(7): 2594.     CrossRef
  • Application of Machine Learning Technique to Distinguish Parkinson’s Disease Dementia and Alzheimer’s Dementia: Predictive Power of Parkinson’s Disease-Related Non-Motor Symptoms and Neuropsychological Profile
    Haewon Byeon
    Journal of Personalized Medicine.2020; 10(2): 31.     CrossRef
  • Exploring the Predictors of Rapid Eye Movement Sleep Behavior Disorder for Parkinson’s Disease Patients Using Classifier Ensemble
    Haewon Byeon
    Healthcare.2020; 8(2): 121.     CrossRef
  • DeepVariant-on-Spark: Small-Scale Genome Analysis Using a Cloud-Based Computing Framework
    Po-Jung Huang, Jui-Huan Chang, Hou-Hsien Lin, Yu-Xuan Li, Chi-Ching Lee, Chung-Tsai Su, Yun-Lung Li, Ming-Tai Chang, Sid Weng, Wei-Hung Cheng, Cheng-Hsun Chiu, Petrus Tang
    Computational and Mathematical Methods in Medicine.2020; 2020: 1.     CrossRef
  • Mini-Review of Laboratory Operations in Biobanking: Building Biobanking Resources for Translational Research
    Mine S. Cicek, Janet E. Olson
    Frontiers in Public Health.2020;[Epub]     CrossRef
  • Development of a depression in Parkinson's disease prediction model using machine learning
    Haewon Byeon
    World Journal of Psychiatry.2020; 10(10): 234.     CrossRef
  • Aspects of Modern Biobank Activity – Comprehensive Review
    Wiktor Paskal, Adriana M. Paskal, Tomasz Dębski, Maciej Gryziak, Janusz Jaworowski
    Pathology & Oncology Research.2018; 24(4): 771.     CrossRef
  • Optimization of RNA Extraction from Formalin-Fixed Paraffin-Embedded Blocks for Targeted Next-Generation Sequencing
    Yoojin Choi, Aeree Kim, Jinkyoung Kim, Jinhwan Lee, Soo Yeon Lee, Chungyeul Kim
    Journal of Breast Cancer.2017; 20(4): 393.     CrossRef
  • Biobank Regulation in South Korea
    Won Bok Lee
    Journal of Law, Medicine & Ethics.2016; 44(2): 342.     CrossRef
  • Standard based Deposit Guideline for Distribution of Human Biological Materials in Cancer Patients
    Hwa Jeong Seo, Hye Hyeon Kim, Jeong Soo Im, Ju Han Kim
    Asian Pacific Journal of Cancer Prevention.2014; 15(14): 5545.     CrossRef
  • Basis for Korean Genome Study
    Hae-Wol Cho, Chaeshin Chu
    Osong Public Health and Research Perspectives.2012; 3(3): 119.     CrossRef

PHRP : Osong Public Health and Research Perspectives